Predominance of CIN versus MSI in the development of rectal cancer at young age

BMC Cancer

Table 1 Summary of clinicopathological data

Tumor no.	Sex/age	Family history (No, Am, Fa, Ud)	Tumor location	Pre-op radio-therapy	Dukes'/TNM stage	Diff. grade	Adjuvant chemo-therapy	Met.free/overall survival (mo.)
1	25/F	No	m	+	C/T4N1M0	mo	FLV	46
2	31/F	No	h	+	C/T3N1M0	mo	FLV	84
3	32/M	Fa	m	+	D/T4N1M1	mo	FLV+OX	0/15
4	32/M	No	m	+	B/T3N0M0	mo	FLV	33
5	33/M	No	m	+	B/T3N0M0	mo	-	85
6	37/M	No	h	-	B/T3N0M0	mo	-	80
7	38/M	No	m	+	A/T2N0M0	mo	-	61
8	38/M	Am	h	-	A/T1N0M0	we	-	49
9	39/M	Ud	l	+	D/T4N2M1	mu, si	-	0/8
10	39/F	Am	h	-	A/T2N0M0	mo	-	32
11	41/M	No	h	+	A/T2N0M0	mu	-	35
12	41/M	Fa	h	+	B/T3N0M0	mo	FLV	34
13	42/M	Fa	l	+	C/T3N1M0	mo	FLV	27
14	43/F	No	h	+	D/T4N2M1	mo	FLV	0/20
15	43/M	No	m	+	C/T3N1M0	mo	FLV	46
16	44/M	No	m	+	B/T3N0M0	po	-	19
17	44/F	Fa	m	-	C/T3N1M0	mu	FLV	10/22
18	45/M	No	m	+	B/T3N0M0	mo	-	71
19	45/M	No	h	+	C/T4N1M0	mo	FLV	55
20	47/M	No	m	-	C/T3N1M0	mo	-	28
21	47/F	Fa	l	+	C/T3N1M0	mo	FLV	24
22	47/M	No	m	-	D/T3N0M1	mo	FLV	0/40
23	47/F	No	l	+	C/T3N2M0	mu, si	FLV	11/17
24	48/M	No	h	+	D/T4N2M1	mo	FLV	0/24
25	49/M	No	h	+	D/T4N2M1	mu	FLV	0/3
26	49/M	Ud	h	+	C/T3N1M0	mo	FLV	27/38
27	49/M	No	h	-	C/T3N2M0	mo	-	62
28	49/M	No	m	+	A/T2N0M0	mo	-	37
29	49/F	No	m	+	A/T2N0M0	mo	-	72
30	49/F	Fa	l	+	C/T3N1M0	mo	-	71

Abbreviations: family history; Am: Amsterdam II criteria fulfilled, Fa: familial, No: no history; Ud:undetermined tumor location; h:high, m:middle, l:low differentiation; we:well, mo:moderate, po:poor, mu:mucinous, si:signet ring cell FLV; 5-FU + leucovorin

ISSN: 1471-2407